Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Potential Pilgrims Aged 56 Years and Older
Conditions
Interventions
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Locations
3
Lebanon
Investigational Site Number : 4220001
Beirut, Lebanon
Investigational Site Number : 7920002
Ankara, Turkey (Türkiye)
Investigational Site Number : 7920001
Ankara, Turkey (Türkiye)
Start Date
April 9, 2019
Primary Completion Date
March 18, 2022
Completion Date
March 18, 2022
Last Updated
March 17, 2025
NCT03537508
NCT03630705
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions